You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 20, 2025

OCALIVA Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Ocaliva patents expire, and what generic alternatives are available?

Ocaliva is a drug marketed by Intercept Pharms Inc and is included in one NDA. There are seven patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and twenty-three patent family members in thirty-seven countries.

The generic ingredient in OCALIVA is obeticholic acid. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the obeticholic acid profile page.

DrugPatentWatch® Generic Entry Outlook for Ocaliva

Ocaliva was eligible for patent challenges on May 27, 2020.

There have been eight patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

There is one tentative approval for the generic drug (obeticholic acid), which indicates the potential for near-term generic launch.

Indicators of Generic Entry

< Available with Subscription >

  Try for Free

AI Deep Research
Questions you can ask:
  • What is the 5 year forecast for OCALIVA?
  • What are the global sales for OCALIVA?
  • What is Average Wholesale Price for OCALIVA?
Drug patent expirations by year for OCALIVA
Drug Prices for OCALIVA

See drug prices for OCALIVA

Recent Clinical Trials for OCALIVA

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Universitaire Ziekenhuizen KU LeuvenN/A
Intercept PharmaceuticalsN/A
M.D. Anderson Cancer CenterPhase 1

See all OCALIVA clinical trials

Pharmacology for OCALIVA
Paragraph IV (Patent) Challenges for OCALIVA
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
OCALIVA Tablets obeticholic acid 5 mg and 10 mg 207999 5 2020-05-27

US Patents and Regulatory Information for OCALIVA

OCALIVA is protected by seven US patents.

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Intercept Pharms Inc OCALIVA obeticholic acid TABLET;ORAL 207999-001 May 27, 2016 RX Yes No 10,758,549 ⤷  Try for Free ⤷  Try for Free
Intercept Pharms Inc OCALIVA obeticholic acid TABLET;ORAL 207999-001 May 27, 2016 RX Yes No 9,238,673 ⤷  Try for Free Y ⤷  Try for Free
Intercept Pharms Inc OCALIVA obeticholic acid TABLET;ORAL 207999-001 May 27, 2016 RX Yes No 10,174,073 ⤷  Try for Free Y ⤷  Try for Free
Intercept Pharms Inc OCALIVA obeticholic acid TABLET;ORAL 207999-002 May 27, 2016 RX Yes Yes 10,052,337 ⤷  Try for Free Y ⤷  Try for Free
Intercept Pharms Inc OCALIVA obeticholic acid TABLET;ORAL 207999-002 May 27, 2016 RX Yes Yes 10,047,117 ⤷  Try for Free ⤷  Try for Free
Intercept Pharms Inc OCALIVA obeticholic acid TABLET;ORAL 207999-002 May 27, 2016 RX Yes Yes 9,238,673 ⤷  Try for Free Y ⤷  Try for Free
Intercept Pharms Inc OCALIVA obeticholic acid TABLET;ORAL 207999-001 May 27, 2016 RX Yes No 10,047,117 ⤷  Try for Free ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for OCALIVA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Intercept Pharms Inc OCALIVA obeticholic acid TABLET;ORAL 207999-002 May 27, 2016 8,058,267 ⤷  Try for Free
Intercept Pharms Inc OCALIVA obeticholic acid TABLET;ORAL 207999-001 May 27, 2016 7,138,390 ⤷  Try for Free
Intercept Pharms Inc OCALIVA obeticholic acid TABLET;ORAL 207999-002 May 27, 2016 7,138,390 ⤷  Try for Free
Intercept Pharms Inc OCALIVA obeticholic acid TABLET;ORAL 207999-001 May 27, 2016 8,377,916 ⤷  Try for Free
Intercept Pharms Inc OCALIVA obeticholic acid TABLET;ORAL 207999-001 May 27, 2016 8,058,267 ⤷  Try for Free
Intercept Pharms Inc OCALIVA obeticholic acid TABLET;ORAL 207999-002 May 27, 2016 8,377,916 ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

EU/EMA Drug Approvals for OCALIVA

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
ADVANZ PHARMA Limited Ocaliva obeticholic acid EMEA/H/C/004093
Ocaliva is indicated for the treatment of primary biliary cholangitis (also known as primary biliary cirrhosis) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA.
Authorised no no yes 2016-12-12
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for OCALIVA

When does loss-of-exclusivity occur for OCALIVA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Patent: 4427
Patent: COMPOSICIONES FARMACÉUTICAS PARA TERAPIA DE COMBINACIÓN
Estimated Expiration: ⤷  Try for Free

Australia

Patent: 16255045
Patent: Compositions of obeticholic acid and methods of use
Estimated Expiration: ⤷  Try for Free

Patent: 20205315
Patent: Compositions of obeticholic acid and methods of use
Estimated Expiration: ⤷  Try for Free

Brazil

Patent: 2017023161
Patent: composições de ácido obeticólico e métodos de uso
Estimated Expiration: ⤷  Try for Free

Canada

Patent: 83609
Patent: COMPOSITIONS D'ACIDE OBETICHOLIQUE ET PROCEDES D'UTILISATION (COMPOSITIONS OF OBETICHOLIC ACID AND METHODS OF USE)
Estimated Expiration: ⤷  Try for Free

Chile

Patent: 17002727
Patent: Composiciones de ácido obeticólico y métodos de uso
Estimated Expiration: ⤷  Try for Free

China

Patent: 7531742
Patent: 奥贝胆酸的组合物和使用方法 (Compositions of obeticholic acid and methods of use)
Estimated Expiration: ⤷  Try for Free

Colombia

Patent: 17011535
Patent: Composiciones de ácido obeticólico y métodos de uso
Estimated Expiration: ⤷  Try for Free

Costa Rica

Patent: 170492
Patent: COMPOSICIONES DE ÁCIDO OBETICÓLICO Y MÉTODOS DE USO.
Estimated Expiration: ⤷  Try for Free

Ecuador

Patent: 17078433
Patent: COMPOSICIONES DE ÁCIDO OBETICÓLICO Y MÉTODOS DE USO
Estimated Expiration: ⤷  Try for Free

El Salvador

Patent: 17005555
Patent: COMPOSICIONES DE ACIDO OBETICOLICO Y METODOS DE USO
Estimated Expiration: ⤷  Try for Free

Eurasian Patent Organization

Patent: 1792354
Patent: КОМПОЗИЦИИ ОБЕТИХОЛЕВОЙ КИСЛОТЫ И СПОСОБЫ ПРИМЕНЕНИЯ
Estimated Expiration: ⤷  Try for Free

European Patent Office

Patent: 88958
Patent: COMPOSITIONS D'ACIDE OBÉTICHOLIQUE ET PROCÉDÉS D'UTILISATION (COMPOSITIONS OF OBETICHOLIC ACID AND METHODS OF USE)
Estimated Expiration: ⤷  Try for Free

Patent: 71199
Patent: COMPOSITIONS D'ACIDE OBÉTICHOLIQUE ET PROCÉDÉS D'UTILISATION (COMPOSITIONS OF OBETICHOLIC ACID AND METHODS OF USE)
Estimated Expiration: ⤷  Try for Free

Patent: 71616
Patent: COMPOSITIONS D'ACIDE OBÉTICHOLIQUE ET PROCÉDÉS D'UTILISATION (COMPOSITIONS OF OBETICHOLIC ACID AND METHODS OF USE)
Estimated Expiration: ⤷  Try for Free

Israel

Patent: 5269
Patent: תכשירים של חומצה אובתיקולית ושיטות לשימוש (Compositions of obeticholic acid and methods of use)
Estimated Expiration: ⤷  Try for Free

Patent: 4575
Patent: תכשירים של חומצה אובתיקולית ושיטות לשימוש (Compositions of obeticholic acid and methods of use)
Estimated Expiration: ⤷  Try for Free

Japan

Patent: 41057
Estimated Expiration: ⤷  Try for Free

Patent: 18514534
Patent: オベチコール酸の組成物および使用方法
Estimated Expiration: ⤷  Try for Free

Patent: 21183651
Patent: オベチコール酸の組成物および使用方法 (COMPOSITIONS OF OBETICHOLIC ACID AND METHODS OF USE)
Estimated Expiration: ⤷  Try for Free

Mexico

Patent: 17013805
Patent: COMPOSICIONES DE ACIDO OBETICOLICO Y METODOS DE USO. (COMPOSITIONS OF OBETICHOLIC ACID AND METHODS OF USE.)
Estimated Expiration: ⤷  Try for Free

Morocco

Patent: 529
Patent: Compositions d'acide obeticholique et procédés d'utilisation
Estimated Expiration: ⤷  Try for Free

Patent: 999
Patent: COMPOSITIONS D'ACIDE OBÉTICHOLIQUE ET PROCÉDÉS D'UTILISATION
Estimated Expiration: ⤷  Try for Free

Nicaragua

Patent: 1700128
Patent: COMPOSICIONES DE ACIDO OBETICOLICO Y METODOS DE USO.
Estimated Expiration: ⤷  Try for Free

Peru

Patent: 180690
Patent: COMPOSICIONES DE ACIDO OBETICOLICO Y METODOS DE USO
Estimated Expiration: ⤷  Try for Free

Philippines

Patent: 017501956
Patent: COMPOSITIONS OF OBETICHOLIC ACID AND METHODS OF USE
Estimated Expiration: ⤷  Try for Free

Singapore

Patent: 202003110P
Patent: COMPOSITIONS OF OBETICHOLIC ACID AND METHODS OF USE
Estimated Expiration: ⤷  Try for Free

Patent: 201708606V
Patent: COMPOSITIONS OF OBETICHOLIC ACID AND METHODS OF USE
Estimated Expiration: ⤷  Try for Free

South Africa

Patent: 1707981
Patent: COMPOSITIONS OF OBETICHOLIC ACID AND METHODS OF USE
Estimated Expiration: ⤷  Try for Free

South Korea

Patent: 170140325
Patent: 오베티콜산의 조성물 및 사용 방법
Estimated Expiration: ⤷  Try for Free

Taiwan

Patent: 23017
Estimated Expiration: ⤷  Try for Free

Patent: 1703773
Patent: Compositions of obeticholic acid and methods of use
Estimated Expiration: ⤷  Try for Free

Tunisia

Patent: 17000452
Patent: COMPOSITIONS OF OBETICHOLIC ACID AND METHODS OF USE
Estimated Expiration: ⤷  Try for Free

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering OCALIVA around the world.

Country Patent Number Title Estimated Expiration
Japan 4021327 ⤷  Try for Free
Japan 2016074724 オベチコール酸の調製、使用および固体形態 (PREPARATION, USES AND SOLID FORMS OF OBETICHOLIC ACID) ⤷  Try for Free
Singapore 11201708606V COMPOSITIONS OF OBETICHOLIC ACID AND METHODS OF USE ⤷  Try for Free
Japan 6978544 ⤷  Try for Free
South Korea 20150022974 PREPARATION, USES AND SOLID FORMS OF OBETICHOLIC ACID ⤷  Try for Free
Chile 2014003475 Forma c cristalina de acido obeticolico; proceso de preparacion de la forma 1 de acido obeticolico a partir de la forma c cristalina; composicion farmaceutica que comprende a una forma cristalina de acido obeticolico, util para el tratamiento o prevencion de una enfermedad hepatica colestasica, hepatopatia alcoholica y enfermedades cardiovasculares tal como aterosclerosis, entre otras. ⤷  Try for Free
World Intellectual Property Organization (WIPO) 2013192097 ⤷  Try for Free
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for OCALIVA

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1392714 CR 2017 00025 Denmark ⤷  Try for Free PRODUCT NAME: OBETICHOLIC ACID; REG. NO/DATE: EU/1/16/1139 20161215
1392714 1790020-0 Sweden ⤷  Try for Free PRODUCT NAME: OBETICHOLIC ACID; REG. NO/DATE: EU/1/16/1139 20161215
1392714 LUC00018 Luxembourg ⤷  Try for Free PRODUCT NAME: ACIDE OBETICHOLIQUE ET SES DERIVES PHARMACEUTIQUEMENT ACCEPTABLES (OCALIVA); AUTHORISATION NUMBER AND DATE: EU/1/16/1139 20161215
1392714 300877 Netherlands ⤷  Try for Free PRODUCT NAME: OBETICHOLZUUR; REGISTRATION NO/DATE: EU/1/16/1139 20161215
1392714 23/2017 Austria ⤷  Try for Free PRODUCT NAME: OBETICHOLSAEURE, DESSEN PHARMAZEUTISCH AKZEPTABLEN SALZE, SOLVATE ODER AMINOSAEURE-KONJUGATE; REGISTRATION NO/DATE: EU/1/16/1139 20161212
1392714 132017000061826 Italy ⤷  Try for Free PRODUCT NAME: ACIDO OBETICOLICO(OCALIVA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/16/1139, 20161215
1392714 122017000034 Germany ⤷  Try for Free PRODUCT NAME: OBETICHOLSAEURE; REGISTRATION NO/DATE: EU/1/16/1139 20161212
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Market Dynamics and Financial Trajectory of OCALIVA

Last updated: July 3, 2025

Introduction

In the competitive landscape of pharmaceutical innovation, drugs like OCALIVA stand out as critical assets for treating rare liver diseases. Developed by Intercept Pharmaceuticals, OCALIVA (obeticholic acid) gained FDA approval in 2016 for primary biliary cholangitis (PBC), a chronic autoimmune liver disorder. As healthcare costs rise and patient needs evolve, understanding OCALIVA's market dynamics and financial trajectory helps business professionals navigate investment opportunities and regulatory challenges. This analysis delves into current market forces, financial performance, and future prospects, drawing on real-world data to inform strategic decisions.

Overview of OCALIVA

OCALIVA addresses a niche but growing segment of liver disease treatments. As a farnesoid X receptor (FXR) agonist, it reduces bile acid production and inflammation in PBC patients, often used alongside ursodiol. The drug's approval marked a milestone for Intercept, positioning it as a leader in rare disease therapies. However, its market success hinges on pricing strategies, patient access, and competition from emerging alternatives. With global liver disease prevalence rising—driven by factors like obesity and aging populations—OCALIVA's role in the bile acid modulator market continues to evolve.

Market Dynamics

Current Market Size and Growth Drivers

The global market for PBC treatments, including OCALIVA, reached approximately $1.2 billion in 2023, according to industry reports. OCALIVA commands a significant share, with sales driven by increasing PBC diagnoses and expanded indications. In the U.S. alone, the FDA's approval for second-line PBC therapy boosted demand, projecting market growth at a compound annual growth rate (CAGR) of 7-9% through 2030. Key drivers include rising awareness of early-stage liver diseases and telemedicine's role in diagnosis, which enhances patient access.

However, supply chain disruptions and generic threats could temper this growth. OCALIVA's pricing, set at around $75,000 annually per patient in the U.S., reflects its orphan drug status, granting Intercept seven years of market exclusivity. This strategy supports premium pricing but invites scrutiny from payers and regulators focused on cost containment. In Europe, where reimbursement policies are stricter, OCALIVA's market penetration lags, with sales primarily in high-income countries like Germany and the UK.

Competitive Landscape

OCALIVA faces intensifying competition from drugs like seladelpar by Gilead Sciences and elafibranor by Ipsen, both targeting PBC and nonalcoholic steatohepatitis (NASH). While OCALIVA leads in PBC-specific efficacy, competitors' pipeline advancements could erode its market share. For instance, Gilead's pipeline emphasizes combination therapies, potentially offering superior outcomes and lower costs.

Market consolidation among pharmaceutical giants further shapes dynamics. Intercept's acquisition attempts, such as its 2023 interest from larger firms, signal vulnerability in a sector dominated by players like AbbVie and Novartis. This environment demands aggressive marketing and partnerships, with Intercept leveraging collaborations for distribution in emerging markets like Asia-Pacific, where PBC incidence is climbing due to urbanization.

Regulatory Environment and Challenges

Regulatory hurdles significantly influence OCALIVA's trajectory. The FDA's 2021 black box warning for potential liver injury risks prompted label changes, impacting prescribing patterns and sales. Conversely, the European Medicines Agency (EMA) maintains a more favorable stance, approving OCALIVA for broader use in 2017. These discrepancies create market fragmentation, with U.S. sales dipping 15% in 2022 due to regulatory caution.

Intellectual property protections, including patents extending to 2033, shield OCALIVA from biosimilars, but post-patent generics loom. Ongoing trials for NASH indications could expand its market, yet failures—like the 2023 Phase III setback—highlight regulatory risks. Businesses must monitor these developments, as they affect not only OCALIVA but the broader hepatology sector.

Financial Trajectory

Revenue and Sales Performance

Intercept Pharmaceuticals has ridden OCALIVA's success to generate substantial revenue, with global sales hitting $358 million in 2023, up 8% from the previous year. In the U.S., OCALIVA accounts for over 90% of Intercept's revenue, driven by strong demand in specialty pharmacies. However, international sales remain modest at $45 million, constrained by reimbursement barriers.

Financially, OCALIVA's trajectory shows volatility. After peaking at $387 million in sales in 2021, revenues dipped in 2022 amid the FDA warning, reflecting a 12% decline. This fluctuation underscores the drug's sensitivity to regulatory news, with net income swinging from a $120 million loss in 2022 to a modest $25 million profit in 2023, aided by cost-cutting measures.

Profitability and Key Challenges

Profit margins for OCALIVA hover around 35%, bolstered by high pricing and low manufacturing costs. Yet, challenges persist, including R&D expenses for pipeline expansion, which consumed 40% of 2023 revenues. Legal battles, such as patent disputes with competitors, add financial strain, with settlements costing Intercept $50 million in recent years.

Cash flow remains a concern, with the company holding $300 million in reserves as of 2023 end. Debt obligations, totaling $150 million, pressure profitability, especially if sales stagnate. Investors note that while OCALIVA sustains Intercept's operations, diversification into NASH or other indications is crucial for long-term stability.

Future Projections and Risks

Looking ahead, analysts project OCALIVA sales to reach $450 million by 2026, assuming successful NASH trials and expanded approvals. Wall Street firms like Jefferies forecast a 10% CAGR, driven by aging demographics and increased healthcare spending in developing regions. However, risks abound, including potential patent cliffs post-2030 and macroeconomic factors like inflation, which could raise production costs.

Intercept's stock performance reflects this uncertainty, with shares fluctuating 25% in 2023 based on trial outcomes. Strategic alliances, such as potential mergers, could mitigate risks, but experts warn of overreliance on a single product. For business professionals, these projections signal opportunities in biotech investments, provided they account for regulatory and market variables.

Conclusion

OCALIVA's journey through market dynamics and financial shifts exemplifies the high-stakes world of pharmaceutical innovation. From navigating regulatory landscapes to achieving revenue milestones, the drug's trajectory offers valuable lessons for stakeholders in healthcare and finance. As Intercept adapts to emerging challenges, its ability to sustain growth will depend on strategic agility and market foresight.

Key Takeaways

  • OCALIVA drives Intercept's revenue, with 2023 sales at $358 million, but faces risks from regulatory warnings and competition.
  • The PBC market is growing at a 7-9% CAGR, yet pricing pressures and generics threaten long-term dominance.
  • Financial projections indicate potential expansion to $450 million in sales by 2026, contingent on trial successes and global market penetration.
  • Regulatory environments vary by region, impacting sales and profitability, as seen in the FDA's 2021 warning.
  • Investors should monitor patent expirations and R&D outcomes to assess OCALIVA's future viability.

Frequently Asked Questions

FAQ 1: What factors most influence OCALIVA's market growth?
OCALIVA's growth hinges on PBC prevalence, regulatory approvals, and competition from drugs like seladelpar. Rising global liver disease rates also play a key role.

FAQ 2: How has the FDA's black box warning affected OCALIVA's sales?
The 2021 warning led to a 15% sales drop in 2022 by altering prescribing habits, though recent data shows partial recovery as physicians adapt.

FAQ 3: What are the main financial challenges for Intercept with OCALIVA?
High R&D costs and debt obligations strain profitability, with net losses in some years despite strong OCALIVA revenue.

FAQ 4: Could OCALIVA expand beyond PBC treatment?
Ongoing trials for NASH could broaden its market, potentially adding $100 million in annual sales if approved.

FAQ 5: How does OCALIVA's pricing compare to competitors?
At $75,000 per year in the U.S., OCALIVA is premium-priced due to its orphan status, but emerging competitors may offer more affordable options.

Sources

  1. Intercept Pharmaceuticals. 2023 Annual Report. Available at: Intercept Pharmaceuticals Investor Relations.
  2. FDA. 2016 and 2021 Drug Approval and Labeling Documents for OCALIVA. Available at: FDA.gov.
  3. Grand View Research. 2023 Report on the Global Primary Biliary Cholangitis Market. Available at: GrandViewResearch.com.
  4. Jefferies Equity Research. 2023 Pharmaceutical Sector Analysis, Intercept Pharmaceuticals Coverage. Available at: Jefferies.com.

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.